script.reportAU
Vaccines

Quadrivalent influenza vaccine (split virion, inactivated)

Brand: Fluarix Tetra

PBAC's latest decision on Quadrivalent influenza vaccine (split virion, inactivated): Recommended with restriction (2019). Considered for Prevention of seasonal influenza in infants and children aged 6 to 35 months of age who have medical conditions associated with an increased risk of influenza disease complications or who are Aboriginal and/or Torres Strait Islander, eligible under the National Immunisation Program.

PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2019
Submissions
1
2019 → 2019

Eligible population

Infants and children aged 6 to 35 months of age who have medical conditions associated with an increased risk of influenza disease complications (such as cardiac disease, chronic respiratory conditions, chronic neurological conditions, immunocompromising conditions, diabetes, renal disease, haematological disorders, or long-term aspirin therapy) or who are Aboriginal and/or Torres Strait Islander, eligible for free vaccination under the National Immunisation Program.

Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Surrogate
Pivotal trial size
753 patients
Key trials
FLU D-QIV-004, FLU D-QIV-009, FLU D-QIV-015, FLU-Q-QIV-022
Comparator
FluQuadri Junior
Economic model
Cost-minimisation
ICER note
This was a minor submission with no economic comparison; cost-minimisation analysis based on price parity with comparator.

Similar precedents

Open on full dashboard →